USL311 is an orally active CXCR4-specific antagonist that inhibits the binding of stromal cell-derived factor-1 (SDF-1/CXCL12) to CXCR4[1-2]. Chemokine C-X-C receptor 4 (CXCR4) is a key axis of normal development and immunity and is often aberrantly expressed in various cancer types[3]. USL311 has anticancer effects, such as in glioblastoma, and can be used in combination with lomustine to treat patients with advanced solid tumors and recurrent GBM[2].
References:
[1]. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1.
[2]. Rueda A, Serna N, Mangues R, et al. Targeting the chemokine receptor CXCR4 for cancer therapies[J]. Biomarker Research, 2025, 13(1): 68.
[3]. MacLean M R, Walker O L, Arun R P, et al. Informed by cancer stem cells of solid tumors: advances in treatments targeting tumor-promoting factors and pathways[J]. International journal of molecular sciences, 2024, 25(7): 4102.